Share Name Share Symbol Market Type Share ISIN Share Description
Beximco Pharma LSE:BXP London Ordinary Share US0885792061 GDR (EACH REPR 1 ORD BDT10)(REGS)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 58.50p 57.00p 60.00p 58.50p 58.50p 58.50p 2,486 07:57:36
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 147.6 27.5 0.1 1,176.6 225.95

Beximco Pharma Share Discussion Threads

Showing 1501 to 1524 of 1525 messages
Chat Pages: 61  60  59  58  57  56  55  54  53  52  51  50  Older
DateSubjectAuthorDiscuss
14/11/2017
10:44
Still haven't found any earnings upgrades for FY18 since the prelims. Assuming that Q1 EPS are maintained for the rest of the year then thats going to beat those forecasts easily.
firtashia
13/11/2017
22:16
25% increase in eps for 1st quarter compared to 1st q 2016!
cockneytrader
07/11/2017
15:50
3800- just a consensus
firtashia
07/11/2017
13:42
Northland Capital have recently taken over as broker for BXP (from Daniel Stewart if memory serves). They released a note this morning (available on Research Tree) but unfortunately have not provided forecasts. 'Results and product launch into US This morning Beximco announced it has commenced the export of Sotalol Hydrochloride (80 mg, 120 mg and 160 mg), a generic version of the cardiovascular drug Betapace, to the US. Following the successful launch of Carvedilol to the US in August 2016, this is the second product from Beximco Pharma to be exported to the US. According to QuintlesIMS data, the market size for Satalol Hydrochloride (including all strengths) in the US is $23 million. Yesterday, Beximco also announced its audited results for the 12 month period ended 30 June 2017. Net sales increased to BDT 15,508.8 million (£147.51 million), registering year-on-year growth of 12.5% (2015-16: BDT 13,785.3 million (£135.7 million)) Export sales registered year-on-year growth of 25.2% Profit before tax increased 12.8% to BDT 2,891.5 million (£27.50 million), (2015-16: BDT 2,564.3 million, £25.24 million) Yesterday Beximco’s results demonstrated that the Company continues to see good YoY growth, registering double-digit Sales and PBT expansion. Of note, the Group continues to show strong export growth. Also, today’s announcement demonstrates Beximco’s continued progress in the US market, with the launch of its second product there.' https://www.research-tree.com/research/northland-capital-partners/northland-capital-partners-limited-morning-report/f99ea779-9dc1-47e9-a5e2-204c07532233
penpont
07/11/2017
12:29
thanks for that firtashia doe's stockopedia give individual brokers forecasts or just a consensus number? 3800
3800
07/11/2017
12:06
3800- Agree about the paucity of forecast info, which I see as a positive. I subscribe to Stockopedia and the FY18 forecasts on there are for EPS of 5.19BDT (down from 5.49BDT for FY17) and FY18 forecast net profit of 2863m BDT (up from 2227m BDT for FY17). Revs are forecast to increase to 20410m BDT (from 15500m in FY17) so thats a very healthy increase. It doesnt look as if they have been updated for quite a while so I am keeping a close eye out to see if they are now updated following yesterdays results.
firtashia
07/11/2017
11:29
I'm just taking a quick look at BXP and cannot find any brokers forecasts the only thing I can find is an article from 5 months ago here hxxps://www.stockopedia.com/content/sif-portfolio-may-review-beximco-pharmaceuticals-amp-xlmedia-190274/ saying that the house broker Daniel Stuart forcasts this years earnings to be 21% less than 2016. Has anyone else access to Forecasts more recent? 3800
3800
07/11/2017
09:44
1st quarter results were on 15th November last year.
mfhmfh
07/11/2017
09:43
2nd product launched in the US with hopefully more to come: 'With our growing pipeline for the US, we will focus on increasing our presence in the world's largest pharma market in the coming years.'
mfhmfh
06/11/2017
14:57
Positive write up on Stockopedia today
mfhmfh
06/11/2017
14:38
agree about the re-rate differentials between us and eu market and other market but it seems odd that growing company with relatively big turnover can have a PE so low, ever stranger that on the day of the result only 50k share change hands. oh well we must do with a divi of approx. 1p a share for now hopefully this will grow quicker in the future
jovi1
06/11/2017
12:25
It will never be rated the same as an Amercian or European Pharmaceuticals company, but they are now turning out consistent figures, with growth, in my opinion the share should be somewhat higher than they are now.
chrisgail
06/11/2017
12:12
solid results with surely growth to come: · Received approvals for two ANDAs from the US Food and Drug Administration (US FDA) · Launched 15 products in the domestic market, four of which were launched for the first time in Bangladesh · Registered 71 new products in 20 countries · Entered seven new markets - Panama, Ecuador, Tanzania, Zimbabwe, Mali, Cameron and Guinea Conakri · Formed the Company's first overseas manufacturing collaboration with the joint venture with BioCare Manufacturing (M) Sdn Bhd based in Malaysia · Granted a sub-license by Medicine Patent Pool of the UN to produce Bristol-Myers Squibb's new hepatitis C drug Daclatasvir · Net sales increased to BDT 15,508.8 million (£147.51 million), registering year-on-year growth of 12.5% (2015-16: BDT 13,785.3 million (£135.7 million)) o Export sales registered year-on-year growth of 25.2% · Profit before tax increased 12.8% to BDT 2,891.5 million (£27.50 million), (2015-16: BDT 2,564.3 million, £25.24 million) All IMHO.
mfhmfh
06/11/2017
11:36
FY results out this morning - happy to hold, will be interested to see in which direction forecast fy18 earnings will be revised.
firtashia
30/10/2017
11:38
Compared to the previous 18 month period eps are up 17% over this 12 month period.
rogash
30/10/2017
10:06
But some figures were given in the announcement. EPS is 5.49BDT for the year. This is disappointing as it shows no growth at all over the 1st half, which was 2.74. The situation is considerably worse if you convert to GBP due to currency changes. Now I know currency fluctuation is out of the control of management, but earnings growth per share in BDT is not.
cb7
26/10/2017
16:29
On the day they announce when the results are going to be announced by, the share price drops, presumably because people dont want to be holding when the results are issued, and for no reason related to the actual performance of the business.
firtashia
12/10/2017
10:35
large volume today
mfhmfh
09/10/2017
09:22
From a commercial point of view this looks to be a potentially very exciting acquisition. It should open up a whole new customer base for cross-selling, especially internationally. I wonder if any of Nuvista's facilities are EU / FDA approved ?
outsizeclothes.com
07/10/2017
14:59
Agree. The shares to avoid are the ones with hundreds of mostly rubbish posts on ADVFN every day. Was originally attracted to BXP by then very high Stockopedia ratings, since when the share price has nearly doubled.
kenmitch
07/10/2017
10:21
happy to be in a 'quiet share'.
mfhmfh
07/10/2017
08:38
Yes. Share price reaction muted, probably because BXP off most investors radar.
kenmitch
06/10/2017
07:50
positive news today
mfhmfh
29/9/2017
14:40
Perhaps Beximco aren't totally sure of just how good their distribution agents, and accordingly their sales people, are ? Better to check that out with smaller value/market size products first, to see if sales are generated, and how quickly. This before committing to supply large amounts of more valuable stock with perhaps a shorter shelf-life, which might, or might not, sell.
outsizeclothes.com
Chat Pages: 61  60  59  58  57  56  55  54  53  52  51  50  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20171119 10:23:14